Company Overview: Illumina, Inc. is a laboratory analytical instruments manufacturer (SIC 3826) headquartered in San Diego, California, with fiscal year ending December 28, 2025. The company operates in the genomics and life sciences sequencing industry. Financial Reporting Structure: The filing contains comprehensive financial statements for fiscal year 2025 (ended December 28, 2025) compared to…

Our analysis rates this filing BEARISH. Illumina faces a HIGH concern level (7.2/10) driven by multiple material headwinds converging simultaneously. The GRAIL spin-off, completed in June 2024, represents a fundamental restructuring that reduces revenue diversification and increases reliance on…

Concern level: HIGH (7.2/10). Key factors: Two high-severity risks identified with severity scores of 8 and 7 (GRAIL spin-off and goodwill/intangible impairments); Overall risk trend is INCREASING with risk score of 7.8/10; GRAIL spin-off represents loss of significant business segment and major revenue diversification reduction.

Notable risk changes: GRAIL Spin-off Completion (June 2024): Major business segment separated as discontinued operation. This represents a fundamental restructuring of the company's business model and revenue base, with material implications for future growth profile and profitability.; Goodwill and Intangible Asset Impairments: 2025 filing shows impairment charges indicating prior acquisitions are underperforming…

The model predicts ILMN will underperform the S&P 500 by about 0.0% over 30 days. This is model analysis for research, not investment advice.